Viracta Therapeutics Ownership
VIRX Stock | USD 0.15 0.01 7.14% |
Shares in Circulation | First Issued 2005-09-30 | Previous Quarter 39.4 M | Current Value 39.6 M | Avarage Shares Outstanding 10.1 M | Quarterly Volatility 15.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Viracta |
Viracta Stock Ownership Analysis
About 50.0% of the company outstanding shares are owned by institutional investors. The book value of Viracta Therapeutics was at this time reported as 0.33. The company recorded a loss per share of 1.1. Viracta Therapeutics last dividend was issued on the 3rd of September 2020. The entity had 285:1000 split on the 25th of February 2021. Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. For more information please call Mark Rothera at 858 400 8470 or visit https://www.viracta.com.Besides selling stocks to institutional investors, Viracta Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Viracta Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Viracta Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Viracta Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Viracta Therapeutics are currently held by insiders. Unlike Viracta Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Viracta Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Viracta Therapeutics' insider trades
Viracta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viracta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viracta Therapeutics backward and forwards among themselves. Viracta Therapeutics' institutional investor refers to the entity that pools money to purchase Viracta Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | United Capital Financial Advisers Inc | 2024-09-30 | 43 K | Northern Trust Corp | 2024-09-30 | 38.1 K | Virtu Financial Llc | 2024-06-30 | 30.8 K | Integrys Wealth Advisors Llc | 2024-09-30 | 25 K | Wealthtrust Axiom Llc | 2024-09-30 | 16.4 K | Beacon Pointe Advisors, Llc | 2024-06-30 | 15 K | Hoylecohen, Llc | 2024-06-30 | 14 K | Tower Research Capital Llc | 2024-06-30 | 12.7 K | Bank Of America Corp | 2024-06-30 | 12.5 K | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 954.5 K |
Viracta Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viracta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viracta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viracta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viracta Therapeutics Outstanding Bonds
Viracta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viracta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viracta bonds can be classified according to their maturity, which is the date when Viracta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
Virgin Media Communications Corp BondUS92769VAJ89 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Viper Energy Partners Corp BondUS92763MAA36 | View | |
Virgin Media 55 Corp BondUS92769XAP06 | View | |
Virgin Media Investment Corp BondUS92769XAR61 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.